Notes
2019 US dollars
Reference
Tan C, et al. Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population. Advances in Therapy : 10 Apr 2021. Available from: URL: http://doi.org/10.1007/s12325-021-01733-7
Rights and permissions
About this article
Cite this article
Tofacitinib cost effective for moderate-to-severe RA in China. PharmacoEcon Outcomes News 877, 23 (2021). https://doi.org/10.1007/s40274-021-7672-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7672-5